On Wednesday, Shares of Twenty-First Century Fox, Inc. (NASDAQ:FOXA), gained 0.58% to $34.56.
FOX News Channel (FNC) and Facebook declared that they will present the first Republican presidential primary debate in conjunction with the Ohio Republican Party on August 6, 2015. The debate will be presented live from the Quicken Loans Arena in Cleveland, OH from 9-11 PM/ET on FNC together with FOX News Radio, FOX News Mobile and FOXNews.com.
FOX News’ Executive Vice President of News Editorial Michael Clemente declared the entry criteria as follows:
- Must meet all U.S. Constitutional requirements; and
- Must declare and register a formal campaign for president; and
- Must file all necessary paperwork with the Federal Election Commission (FEC); and
- Must have paid all necessary federal and state filing fees; and
- Must place in the top 10 of an average of the five most recent national polls, as recognized by FOX News leading up to August 4th at 5 PM/ET. Such polling must be conducted by major, nationally recognized organizations that use standard methodological techniques.
Twenty-First Century Fox, Inc. operates as a diversified media and entertainment company worldwide. It operates through Cable Network Programming, Television, Filmed Entertainment, and Direct Broadcast Satellite Television segments.
Shares of Liberty Global plc (NASDAQ:LBTYA), inclined 4.31% to $55.40, during its last trading session, hitting its highest level.
Liberty Global, declared that it intends to implement its formerly declared tracking stock for its operations in Latin America and the Caribbean on July 1, 2015. At the close of trading on the distribution date, Liberty Global will distribute, as a dividend, to holders of its Class A, Class B and Class C ordinary shares as of 5:00 p.m. Eastern time on June 24, 2015, one share of the corresponding class of LiLAC Group ordinary shares for each 20 Liberty Global ordinary shares held by each shareholder as of the record date. Cash will be issued in lieu of fractional LiLAC Group ordinary shares.
Liberty Global plc, together with its auxiliaries, provides video, broadband Internet, fixed-line telephony, and mobile services in Europe, Chile, Puerto Rico, and internationally.
Finally, Celgene Corporation (NASDAQ:CELG), ended its last trade with 0.01% gain, and closed at $116.86.
On April 30, Celgene Corporation stated net product sales of $2,055 million for the first quarter of 2015. Net product sales grew 20 percent from the same period in 2014 with operational growth of 22 percent. The negative net impact of currency on net product sales was 2 percent. First quarter total revenue raised 20 percent to $2,081 million contrast to $1,730 million in the first quarter of 2014. Adjusted net income for the first quarter of 2015 raised 26 percent to $891 million contrast to $705 million in the first quarter of 2014. For the same period, adjusted diluted earnings per share (EPS) raised 29 percent to $1.07 from $0.83, on a stock split-adjusted basis.
Based on U.S. GAAP (Generally Accepted Accounting Principles), Celgene stated first quarter of 2015 net income of $719 million or $0.86 per diluted share. For the first quarter of 2014, net income was $280 million or $0.33 per diluted share, on a stock split-adjusted basis.
Net Product Sales Performance
- REVLIMID® sales for the first quarter raised 17 percent to $1,343 million which comprises a negative net impact of foreign exchange of $22 million (1.9 percent). Growth was driven by enhances in overall market share and duration of therapy. U.S. sales of $811 million and International sales of $532 million raised 26 percent and 6 percent, respectively.
- ABRAXANE® sales for the first quarter were $223 million, a 21 percent enhance. U.S. sales of $159 million and International sales of $64 million raised 12 percent and 48 percent, respectively. The enhance in sales reflects the impact of broad use in breast, lung and pancreatic cancers in the U.S. and early launch success for pancreatic cancer in Europe.
- POMALYST®/IMNOVID® sales were $199 million, a 46 percent enhance year-over-year. U.S. sales of $129 million and International sales of $70 million raised 45 percent and 49 percent, respectively. POMALYST®/IMNOVID® sales were driven by market share gains and increasing duration in the U.S. and Europe.
- VIDAZA® first quarter sales reduced 3 percent to $144 million. U.S. sales reduced 60 percent to $6 million influenced by the introduction of generic azacitidine in September 2013. International sales were $138 million and raised 3 percent. International sales were driven by raised demand in Europe.
- OTEZLA® sales in the first quarter of 2015 were $60 million. OTEZLA® uptake and market share gains have been strong in the U.S. since the first approval in March 2014. Prescription trends continue to accelerate since the U.S. approval for psoriasis in September 2014.
- All other product sales, which comprise THALOMID®, ISTODAX® and an authorized generic of VIDAZA® drug product in the U.S., were $86 million in the first quarter of 2015 contrast to $95 million for the first quarter of 2014.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID for the treatment of multiple myeloma; and VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, in addition to acute myeloid leukemia (AML).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
